Marketing Authorization Application for Lipsovir® submitted to European regulatory authorities.

Medivir has now submitted an application for marketing authorization to the European regulatory authorities for Lipsovir®, a topical product for prevention and treatment of cold sores.

Lipsovir® is a patented combination of hydrocortisone (an anti-inflammatory agent) and acyclovir (an antiviral agent) in a proprietary cream base developed by Medivir.

The clinical phase III program demonstrated that the development of cold sores can be prevented with early treatment initiation, an effect that currently available products for this indication lack. Lipsovir® thereby provides individuals prone to recurrent cold sores with a clinically important benefit compared to currently available products.

“We have achieved a substantial and important milestone for Lipsovir® in filing registration applications in both USA and Europe”, says Börje Darpö, Head of Medivir’s clinical development department.

For additional information please contact
Rein Piir, CFO & VP, Investor Relations at Medivir, +46 8 5468 3123 or +46 708 537292

For more information on Medivir, please see the company website

About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR).


Documents & Links